knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 23:11:59 - browse：238

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA clears Verve to begin U.S. study of gene

WSS

FDA clears Verve to begin U.S. study of gene

STAT Readout Newsletter: Biotech news today

A new crop of companies is reshaping the health data economy

Will the FTC rein in IQVIA's health data empire?

Democrats decry new health bill for going easy on private equity

Former reverend arrested for allegedly killing 8

hotspot

knowledge

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: The economic case for universal basic health care

After affirmative action ruling, medical educators look to 'holistic review'

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

23andMe had bad news about my health. I wish a person had delivered it

Roche acquires Telavant from Roivant, adding experimental IBD treatment

BioMarin wins approval for gene therapy to treat hemophilia A

Merck, Daiichi strike cancer drug pact worth up to $22 billion

DIEP, the 'gold standard' of breast reconstruction, is under threat

UHS says company favors patients whose insurance pays more

leisure time

Roche’s Alnylam deal shows drug firms interested in heart drugs

Why patients can’t get everything they want on drug pricing

How AI can help patients find reliable information about doctors

Biogen says it will cut costs by $700 million, slash 1,000 jobs

The problems with dementia villages

The battle over 'scope creep' and who gets to be called 'doctor'

entertainment

hotspot

explore

knowledge